Horizon Europe Avrupa Birliği
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · Avrupa Birliği
Clinical trials for advancing innovative interventions for neurodegenerative diseases
Açık
AB Ufuk Avrupa programı tarafından 4 hibe bekleniyor; proje başına €10 milyon; toplam bütçe €39,3 milyon. Başvurular 17 Şubat 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.
- Son başvuru
- 17 Şubat 2027 (94 gün kaldı)
- Hibe tutarı
- Proje başına €10 milyon
- Toplam bütçe
- €39,3 milyon
- Destek oranı
- Uygun maliyetlerin %100’ü Bu program için standart kural; çağrı farklı olabilir.
- Toplam bütçe
- €39,3 milyon
- Beklenen hibe sayısı
- 4
- Faaliyet türü
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Olası başvuru sahipleri
- Şirketler, KOBİ’ler / girişimler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma, Kamu kurumları Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
- Fon sağlayıcı
- Horizon Europe (HORIZON)
- Referans
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage
- Çağrı
- HORIZON-HLTH-2027-02-two-stage
- Son kontrol
- 14 Kasım 2026
Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.
Beklenen sonuçlar
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases.
• The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond.
• The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data.
Tam metni oku
• Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
• Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.
Kapsam
Neurodegenerative diseases are a high burden for patients, caregivers, health systems and society. Given the limitations with current therapeutic solutions, including that they primarily address symptoms rather than underlying causes and can have serious side effects, together with the increasing prevalence of neurodegenerative diseases in an aging population, there is a huge need to develop more innovative, safer and more effective therapeutic solutions for these diseases. To further enhance their safety and effectiveness, the therapeutic solution based on an active substance should be combined/complemented with another multidisciplinary approach (e.g. lifestyle changes, cognitive training, rehabilitation therapies). Together this innovative intervention should lead to an improved quality of life and reduce the societal impact of these diseases.
Rare neurodegenerative diseases are excluded [2] .
Tam metni oku
Proposals should address most of the following aspects:
• Perform rigorous early-stage [3] clinical trials into the safety and efficacy of the innovative interventions and their mode of administration, ensuring adequate cohorts/sample sizes with adequate representation of the patient population, including in terms of age, sex and ethnicity.
• Through the clinical trials and to the extent possible of additional studies, gain further insight into the potentially novel mechanism(s) of action of the innovative therapies and complementary approaches. This could entail analyses of imaging (e.g. MRI, ultrasound, nuclear imaging), as well as physiological, molecular, biochemical or omics signatures revealing potential perturbations prior to the intervention and recovery/improvement thereafter, and it could lead to the development of surrogate endpoints. This insight should open the path to more personalised interventions and approaches.
• Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence - AI [4] , wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disorder and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound.
• Utilise existing data, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles.
• Engage all relevant stakeholders (especially patients and patients’ representatives for the disease, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions, applying gender-sensitive and intersectional approaches.
• Advance research by leveraging already existing and emerging state-of-the-art research infrastructures (e.g. EuroBioImaging [5] , European Genomic Data Infrastructure [6] , ECRIN [7] , EATRIS [8] , EBRAINS [9] , BBMRI [10] , etc.), as well as results stemming from…
Kimler başvurabilir
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.
Konular
Brain research Clinical medicine Clinical neurology Clinical research Clinical trials Cognition (e.g. learning, memory, emotions, speech) Dementia Interventional clinical trials Molecular and cellular neuroscience Neurobiology Neurochemistry and neuropharmacology Neurodegenerative disorders Neuroinflammatory disorders Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) Neurology Neurosciences (including psychophysiology) Public health Interventions Neurodegeneration Neurodegenerative diseases
Zamanlama
Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
Nasıl başvurulur
- Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
- Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
- İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
- Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
- Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Resmi kaynaklar
Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.
Horizon Europe: diğer çağrılar
Horizon Europe Avrupa Birliği
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe Avrupa Birliği
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe Avrupa Birliği
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe Avrupa Birliği
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…